Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.65 |
| ▸ | KDR | P35968 | 6/20 | 0.65 |
| ▸ | AXL | P30530 | 2/20 | 0.65 |
| ▸ | FLT3 | P36888 | 2/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.65 |
| ▸ | MST1R | Q04912 | 16/20 | 0.56 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | ABL2 | P42684 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL26110839 | 1.00 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| Malic Acid SCHEMBL29910999 | 1.00 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL103903 | 0.94 | MET (0.73) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL29514769 | 0.94 | MET (0.73) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL104989 | 0.91 | MET (0.67) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL2534615 | 0.89 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL2670680 | 0.88 | MET (0.64) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29514793 | 0.86 | MET (0.87) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29911094 | 0.86 | MET (0.87) | METKDRAXLFLT3NTRK1 | |
| Sitravatinib SCHEMBL29927156 | 0.86 | MET (0.87) | METKDRAXLFLT3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787819-B2 | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | MIRATI THERAPEPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220289760-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. | 2022-09-15 | — | — | US | disclosed |
| WO-2022192507-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289760-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | LCK, MAP2K5, SRC | MET 14/4885KDR 733/4885AXL 206/4885 |
| US-11787819-B2 | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | LCK, MAP2K5, SRC | MET 14/4885KDR 733/4885AXL 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.